The HEOR team of Hardian Health is offering a new service for digital health companies to support them with evidence generation when their products are evaluated post-market through randomised controlled trials.

Our new package involves the analysis of primary data to estimate health outcomes, costs, and Incremental Cost-Effectiveness Ratios (ICERs) for decision making. By leveraging primary data collection, health outcomes and costs derived from randomised trials can also be extrapolated as robust inputs for subsequent, post-market cost-effectiveness models.

Software and AI medical devices (AI/SaMD) are solving clinical problems at speed. Healthcare systems, though, won't adopt a technology that works brilliantly if they can't make an economic case for it. At the Hardian Summit 2026, we hosted a workshop on Health Economics and Outcomes Research for professionals new to the field.